Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Breast Cancer Clinical Trial

Official title:

A Phase I Study Of Weekly Taxotere (Docetaxel) And Gleevec (STI571, Imatinib Mesylate, CGP 57148B) In Locally Advanced Or Metastatic Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00080665
• Other study ID #: J0214 CDR0000354504
• Secondary ID: P30CA006973JHOC-
• Status: Completed
• Phase: Phase 1
• First received: April 7, 2004
• Last updated: April 22, 2018
• Start date: December 2003
• Est. completion date: January 2011

Study information

• Verified date: April 2018
• Source: Sidney Kimmel Comprehensive Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy such as docetaxel work in different ways to stop tumor cells from dividing so they stop growing or die. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Giving docetaxel with imatinib mesylate may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of docetaxel when given together with imatinib mesylate in treating patients with locally advanced or metastatic breast cancer.

Description:

OBJECTIVES:

Primary

• Determine the safety profile, maximum tolerated dose, and recommended phase II dose of docetaxel when administered with imatinib mesylate in patients with locally advanced or metastatic breast cancer.

Secondary

• Determine the pharmacokinetic profile of this regimen in these patients.

• Determine the potential effects of this regimen on CYP3A4 activity and docetaxel metabolism in these patients.

• Correlate docetaxel and imatinib mesylate exposure (utilizing total and unbound docetaxel and imatinib mesylate plasma concentrations) with drug response (e.g., pharmacodynamic effects, drug toxicity, and response) in these patients.

• Determine response rate, duration of response, and time to treatment failure in patients treated with this regimen.

• Correlate proteomic profile changes in serum with tumor burden and response in patients treated with this regimen.

• Correlate pharmacokinetic parameters, tissue expression of specific receptor tyrosine kinases (e.g., c-Kit, platelet-derived growth factor receptor [PDGFR], and phosphorylated PDGFR) in paraffin blocks, and pharmacodynamic assays with antitumor activity of this regimen in these patients.

OUTLINE: This is an open-label, dose-escalation study of docetaxel.

Patients receive docetaxel IV over 1 hour on days 1, 8, and 15 and oral imatinib mesylate (STI571) on days 8-28 of course 1 and days 1-28 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity*. Patients with stable or responding disease after at least 2 courses of therapy may discontinue docetaxel and continue therapy with single-agent STI571 until disease progression.

NOTE: *Patients experiencing excessive docetaxel-related toxicity who have completed at least 2 full courses may continue on single-agent STI571 in the absence of disease progression or excessive STI571-related toxicity.

Cohorts of 3-6 patients receive escalating doses of docetaxel until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional cohort of 6-12 patients receives treatment at the MTD.

Patients are followed at 30 days.

PROJECTED ACCRUAL: Approximately of 18-30 patients will be accrued for this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: January 2011
• Est. primary completion date: January 2007
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• Histologically confirmed adenocarcinoma of the breast

• Stage IIIB, IIIC, or IV disease

• Measurable or evaluable disease

• Stable brain metastases allowed provided prior surgery or radiotherapy was completed more than 90 days ago

• No documented or suspected leptomeningeal disease

• Hormone receptor status:

• Not specified

PATIENT CHARACTERISTICS:

Age

• 18 and over

Sex

• Male or female

Menopausal status

• Not specified

Performance status

• ECOG 0-1

Life expectancy

• Not specified

Hematopoietic

• Granulocyte count = 1,500/mm^3

• Hemoglobin = 8.0 g/dL

• Platelet count = 100,000/mm^3

Hepatic

• Bilirubin = upper limit of normal (ULN)

• Meets 1 of the following criteria for AST or ALT AND alkaline phosphatase:

• AST or ALT = ULN AND alkaline phosphatase = 5 times ULN

• AST or ALT = 2.5 times ULN AND alkaline phosphatase = ULN

• AST or ALT = 1.5 times ULN AND alkaline phosphatase = 2.5 times ULN

• No known acute or chronic liver disease (e.g., chronic active hepatitis or cirrhosis)

Renal

• Creatinine = 1.5 mg/dL

Cardiovascular

• No New York Heart Association class III or IV heart disease

• No congestive heart failure

• No myocardial infarction within the past 6 months

Other

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception during and for at least 3 months after study participation

• No other primary malignancy except those malignancies that are clinically insignificant AND do not require active intervention

• No other concurrent severe and/or life-threatening medical disease

• No significant history of noncompliance to medical regimens or inability to grant reliable informed consent

PRIOR CONCURRENT THERAPY:

Biologic therapy

• At least 14 days since prior systemic trastuzumab (Herceptin®)

• No concurrent trastuzumab

• No concurrent biologic therapy for the primary malignancy

Chemotherapy

• Prior taxane therapy, including docetaxel, in the adjuvant or metastatic setting allowed

• At least 21 days since prior systemic chemotherapy (14 days for weekly or oral chemotherapy and 42 days for nitrosoureas or mitomycin)

• No other concurrent chemotherapy

Endocrine therapy

• At least 14 days since prior systemic hormonal therapy

• No concurrent antiestrogen therapy

• No concurrent routine systemic corticosteroid therapy except as premedication for chemotherapy

• Concurrent megestrol allowed only as an appetite stimulant

Radiotherapy

• See Disease Characteristics

• At least 14 days since prior radiotherapy

• No prior radiotherapy to only site of measurable/evaluable disease unless there is new evidence of post-radiotherapy disease progression

• No concurrent radiotherapy

Surgery

• See Disease Characteristics

• More than 2 weeks since prior major surgery

Other

• Recovered from all prior therapy

• At least 14 days since prior daily or weekly systemic investigational treatment

• No concurrent warfarin for full anticoagulation

• Concurrent low-dose warfarin (e.g., 1 mg/day) allowed for prophylaxis of central venous access

• No concurrent treatment with any of the following:

• Phenobarbital

• Phenytoin

• Carbamazepine

• Barbiturates

• Rifampin

• Hypericum perforatum (St. John's wort)

• No other concurrent therapies for the primary malignancy

• No other concurrent investigational drugs or systemic therapy

• No concurrent bisphosphonates unless started before study therapy

• No concurrent grapefruit juice

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• docetaxel
Docetaxel (15-30 mg/m2, IV, weekly on days 1, 8, and 15) each 28 day cycle
• imatinib mesylate
Imatinib mesylate (400-600 mg, oral, once daily) each 28 day cycle

Locations

Country	Name	City	State
United States	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Baltimore	Maryland

Sponsors (2)

Lead Sponsor	Collaborator
Sidney Kimmel Comprehensive Cancer Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Connolly RM, Rudek MA, Garrett-Mayer E, Jeter SC, Donehower MG, Wright LA, Zhao M, Fetting JH, Emens LA, Stearns V, Davidson NE, Baker SD, Wolff AC. Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast c — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	2.1.1 To determine the safety profile, maximum tolerated dose, and recommended dose for subsequent phase II studies of a combination regimen of daily STI571 with weekly docetaxel on days 1, 8, and 15 in a 28-day cycle.		4 weeks